Abstract

The PD-L1 overexpression is an important event of immune escape and metastasis in triple-negative breast cancer (TNBC), but the molecular mechanism remains to be determined. Interferon gamma (IFNγ) represents a major driving force behind PD-L1 expression in tumor microenvironment, and histone deacetylase 2 (HDAC2) is required for IFN signaling. Here, we investigated the regulation of HDAC2 on the IFNγ-induced PD-L1 expression in TNBC cells. We found the HDAC2 and PD-L1 expression in TNBC was significantly higher than that in non-TNBC, and HDAC2 was positively correlated with PD-L1 expression. HDAC2 promoted PD-L1 induction by upregulating the phosphorylation of JAK1, JAK2, and STAT1, as well as the translocation of STAT1 to the nucleus and the recruitment of STAT1 to the PD-L1 promoter. Meanwhile, HDAC2 was recruited to the PD-L1 promoter by STAT1, and HDAC2 knockout compromised IFNγ-induced upregulation of H3K27, H3K9 acetylation, and the BRD4 recruitment in PD-L1 promoter. In addition, significant inhibition of proliferation, colony formation, migration, and cell cycle of TNBC cells were observed following knockout of HDAC2 in vitro. Furthermore, HDAC2 knockout reduced IFNγ-induced PD-L1 expression, lymphocyte infiltration, and retarded tumor growth and metastasis in the breast cancer mouse models. This study may provide evidence that HDAC2 promotes IFNγ-induced PD-L1 expression, suggesting a way for enhanced antitumor immunity when targeting the HDAC2 in TNBC.

Highlights

  • Triple-negative breast cancer (TNBC), accounting for 15–20% of breast cancer cases, represents a more biologically aggressive cluster with rapid proliferation, high rates of relapse, frequently occurring metastasis, and poor prognosis [1]

  • The expression of histone deacetylase 2 (HDAC2) and programmed cell death ligand 1 (PD-L1) was higher in TNBC than that in other breast cancer subtypes In initial experiments, we elucidated the expression of HDAC2 and PD-L1 (CD274) from two online websites, including bcGenExMiner v4.5 and GEPIA2

  • Correlation analysis from bc-GenExMiner v4.5 revealed that the expression of HDAC2, as well as JAK1, JAK2, and STAT1, was significantly correlated with that of PD-L1 in breast cancer (Fig. 1D, Fig. S1)

Read more

Summary

Introduction

Triple-negative breast cancer (TNBC), accounting for 15–20% of breast cancer cases, represents a more biologically aggressive cluster with rapid proliferation, high rates of relapse, frequently occurring metastasis, and poor prognosis [1]. TNBC does not respond to hormonal or HER2-targeted therapies due to the lack of molecular targeted receptors like ER, PR, and HER2/neu [2]. The clinical need of effective therapeutic approaches for TNBC patients is dramatically emerging. Immunologic escape intently engages in the progression of TNBC [3]. The expression of programmed cell death ligand 1 (PD-L1) on the surface of cancer cells, a key immune checkpoint molecule, interacts with its receptor-programmed cell death (PD-1) on immune cells, and counteracts the TCR cascade through phosphorylation of PTPN11 to neutralize cytotoxic T-cell activity [4]. Disrupting of PD-1/PD-L1 interactions by using antibodies can prevent T-cell suppression

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call